Clinical Trial Update: Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating vaccinia virus-based immunotherapy plus sorafenib versus sorafenib alone in hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• vaccinia virus-based immunotherapy

Snippet

Sponsor: SillaJen, Inc. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: COMPLETED | Results posted: 2020-12-16